Pfizer Limited

NSE: PFIZER · Healthcare

₹3,856.00-0.02%06 Nov 2026

Ask the data

Instant answers about Pfizer Limited — computed from its filings, no language model

Market cap₹17,641 cr

Current price₹3,856.00

High / Low₹5,318 / ₹3,612

P/E20.5

P/B4.02

Book value₹958.6

ROE19.6%

ROCE26.6%

Debt / equity0.00

Dividend yield4.26%

EPS (TTM)₹187.84

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	1,980	2,082	2,152	2,239	2,611	2,425	2,193	2,281	2,520
EBITDA	500	565	573	712	836	809	635	740	904
Operating margin	25.3%	27.2%	26.6%	31.8%	32.0%	33.4%	29.0%	32.4%	35.9%
Interest	0	1	11	15	10	13	15	8	9
Depreciation	66	71	103	109	115	106	62	61	58
Profit before tax	548	660	642	669	773	824	746	1,016	976
Tax	188	231	133	171	160	200	195	248	253
Net profit	0	0	509	498	613	624	551	768	722
EPS ₹	78.70	93.78	111.28	108.77	133.89	136.38	120.51	167.79	157.92
Operating cash flow	—	—	—	—	667	356	257	660	968
Capex	—	—	—	—	15	65	19	28	25
Dividend paid	—	—	—	—	160	297	183	160	752
Total assets	—	—	—	—	—	4,001	4,229	4,911	4,922
Equity	—	—	—	—	—	3,207	3,596	4,217	4,203

Quarterly performance

last 35 quarters · ₹ crore

showing latest 8 of 35 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25*	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	520	512	520	514	536	544	567	538	502	515	595	593	535	749	636	676	550	593	637	622	573	531	575	540	547	563	589	538	54	603	642	645	629	653	727
Operating profit	138	130	130	154	151	166	164	133	109	186	203	197	126	286	189	195	165	192	232	203	182	111	183	153	189	177	189	146	82	210	230	228	236	248	261
Operating margin	26.6%	25.4%	25.0%	30.0%	28.2%	30.5%	29.0%	24.8%	21.7%	36.2%	34.1%	33.2%	23.5%	38.1%	29.8%	28.9%	30.1%	32.4%	36.3%	32.7%	31.8%	20.8%	31.7%	28.3%	34.7%	31.5%	32.2%	27.1%	151.2%	34.8%	35.8%	35.4%	37.5%	37.9%	35.9%
Other income	31	31	37	64	35	36	45	58	45	17	12	15	37	12	15	18	17	18	24	27	31	33	36	36	75	42	43	43	2	67	42	38	41	45	47
Interest	-0	0	0	0	1	2	3	2	4	3	5	4	4	2	2	2	4	4	3	4	3	3	3	3	7	2	2	2	1	3	2	2	2	1	3
Depreciation	17	18	18	18	18	25	25	25	28	27	28	27	27	27	27	27	34	27	26	26	26	16	15	18	14	15	15	15	2	14	14	14	15	14	14
Profit before tax	153	142	149	201	168	175	181	164	122	173	183	180	132	269	175	184	145	43	415	201	165	126	201	176	244	203	215	172	253	260	255	192	269	277	423
Tax	48	50	53	69	59	62	27	25	19	49	52	39	32	69	32	40	19	11	104	50	35	32	52	46	65	52	57	45	50	68	66	50	69	72	110
Net profit	0	0	0	0	0	113	154	139	103	124	131	141	101	200	143	144	126	33	311	151	130	94	149	130	179	151	158	128	203	192	189	142	200	204	313
EPS ₹	22.84	20.07	20.94	28.84	23.93	24.66	33.72	30.40	22.52	27.20	28.71	30.87	21.98	43.69	31.25	31.46	27.50	7.11	67.99	32.93	28.34	20.44	32.56	27.12	22.33	32.94	34.61	27.89	44.45	41.91	41.32	31.01	43.68	44.69	68.47
Revenue YoY	—	—	—	—	3.0%	6.3%	9.1%	4.7%	-6.3%	-5.4%	5.0%	10.3%	6.5%	45.5%	6.9%	13.9%	2.8%	-20.9%	0.2%	-8.0%	4.2%	-10.4%	-9.8%	-13.2%	-4.5%	5.9%	2.3%	-0.4%	-90.1%	7.1%	9.1%	19.9%	1067.0%	8.3%	13.2%
Profit YoY	—	—	—	—	—	—	—	—	—	10.3%	-14.8%	1.6%	-2.4%	60.6%	8.8%	1.9%	25.1%	-83.7%	117.6%	4.7%	3.1%	187.3%	-52.1%	-13.7%	38.0%	61.1%	6.3%	-1.8%	13.7%	27.2%	19.4%	11.2%	-1.7%	6.6%	65.7%

Earlier results (standalone, Nov '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Pfizer Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	1,095	1,050	1,112	1,500	2,017	2,022
Operating profit	197	188	239	298	431	349
Operating margin	18.0%	17.9%	21.5%	19.9%	21.4%	17.3%
Other income	91	105	109	56	86	101
Interest	—	2	0	0	1	1
Depreciation	10	8	8	71	124	63
Profit before tax	278	694	340	203	402	517
Tax	93	191	119	107	179	180
Net profit	185	503	221	95	223	337

Quarters

showing latest 8 of 40 periods

	NOV '07†	FEB '08†	MAY '08†	AUG '08†	NOV '08†	FEB '09†	MAY '09†	AUG '09†	NOV '09†	FEB '10†	MAY '10†	AUG '10†	NOV '10†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	177	150	163	188	185	190	193	210	203	208	223	237	261	261	290	271	273	243	269	257	282	266	299	272	274	266	296	474	463	484	512	506	515	501	558	510	453	433	571	457
Operating profit	19	34	37	39	27	44	33	49	30	52	36	52	48	42	52	52	51	32	62	40	54	45	75	46	73	62	50	61	125	112	114	82	123	101	91	62	95	77	167	118
Operating margin	10.6%	22.5%	22.6%	21.0%	14.5%	22.9%	17.1%	23.4%	15.0%	24.9%	16.2%	22.1%	18.5%	16.0%	17.8%	19.2%	18.8%	13.3%	22.9%	15.6%	19.2%	16.8%	24.9%	17.0%	26.6%	23.4%	16.9%	12.8%	26.9%	23.1%	22.3%	16.2%	23.9%	20.2%	16.4%	12.2%	20.9%	17.7%	29.3%	25.8%
Other income	22	18	25	22	20	19	22	16	15	15	21	16	20	22	22	23	24	25	23	26	31	30	34	28	16	10	10	17	19	17	16	24	28	22	24	27	29	27	24	32
Interest	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	2	2	2	2	4	2	2	—	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	33	34	31	30	31	32	15	16	15	16	15	16	18
Profit before tax	37	260	59	58	42	60	48	63	39	65	54	64	66	62	71	72	73	436	78	96	84	73	107	73	87	70	-18	41	110	97	111	75	120	115	203	92	107	89	175	132
Tax	15	67	21	20	11	21	17	22	13	22	20	22	22	20	24	24	24	107	26	32	26	25	37	25	31	24	-6	22	67	44	49	34	53	35	76	30	39	31	64	45
Net profit	22	193	38	38	30	39	31	41	25	42	35	42	44	41	47	48	48	329	52	64	58	48	70	48	56	46	-12	18	43	54	62	40	67	80	126	62	68	57	111	87
EPS ₹	7.39	64.64	12.71	12.76	10.13	13.07	10.49	13.79	8.51	14.23	11.63	14.24	14.60	13.82	15.75	16.18	16.12	110.21	17.52	21.41	19.49	15.96	23.32	15.95	18.78	15.47	-3.97	4.01	9.33	11.77	13.47	8.82	14.64	17.50	27.61	13.63	14.87	12.50	24.29	19.07
Revenue YoY	—	—	—	—	4.2%	—	17.9%	11.9%	9.8%	9.1%	16.0%	12.7%	28.6%	—	—	—	—	-7.1%	-7.3%	-5.0%	3.0%	9.7%	11.3%	5.9%	-2.6%	0.0%	-0.8%	74.2%	68.7%	81.9%	72.7%	6.6%	11.2%	3.5%	8.9%	0.9%	-12.0%	-13.7%	2.4%	-10.5%
Profit YoY	—	—	—	—	37.0%	—	-17.5%	8.1%	-16.0%	8.8%	10.9%	3.2%	71.6%	—	—	—	—	697.5%	11.3%	32.3%	20.9%	-85.5%	33.1%	-25.5%	-3.7%	-3.1%	-117.0%	-61.4%	-23.8%	16.6%	—	119.6%	56.9%	48.7%	104.9%	54.6%	1.6%	-28.6%	-12.0%	39.9%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 32 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	21.0%	21.3%	19.5%	21.4%	16.0%	15.3%	15.3%	16.9%	16.5%	16.4%	15.2%	16.1%	18.5%	18.9%	17.2%	17.5%	19.6%
ROCE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	27.4%	28.1%	26.1%	28.6%	21.5%	20.7%	21.2%	23.3%	22.7%	22.6%	20.2%	21.5%	24.6%	25.2%	23.4%	23.8%	26.6%
Net margin	0.0%	0.0%	5.3%	12.4%	18.6%	23.7%	24.5%	23.2%	22.7%	22.2%	23.2%	23.3%	22.6%	23.5%	18.1%	25.0%	25.8%	25.7%	29.0%	22.7%	22.6%	25.1%	27.4%	27.6%	27.5%	36.7%	38.2%	38.7%	37.3%	28.7%	28.6%	32.4%
EBITDA margin	26.8%	27.2%	28.5%	29.4%	28.1%	26.6%	27.9%	29.4%	31.5%	31.8%	32.8%	31.7%	30.7%	32.0%	30.2%	31.9%	33.0%	33.4%	30.8%	29.5%	28.3%	29.0%	31.6%	31.7%	31.4%	34.1%	35.1%	36.3%	38.6%	35.9%	36.6%	36.7%
Debt / equity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	1151.41	512.56	212.81	128.85	88.86	60.22	55.73	47.58	44.35	45.26	54.25	64.80	75.64	74.68	47.09	61.37	55.68	62.54	72.82	58.78	61.69	49.41	57.17	60.75	66.84	123.27	113.01	117.57	113.31	103.92	130.11	131.22
Asset turnover	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.64	0.63	0.61	0.59	0.57	0.55	0.52	0.53	0.50	0.50	0.35	0.36	0.40	0.42	0.51	0.52	0.50

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	46	46	46	46	46	46	46	46	46
Other equity / reserves	2,870	3,162	3,227	3,550	3,705	4,172	3,803	4,157	4,340
Total equity	2,916	3,207	3,273	3,596	3,751	4,217	3,848	4,203	4,385
Borrowings	2	2	2	2	2	2	2	2	2
Current liabilities	764	657	614	547	605	570	646	627	685
Non-current liabilities	150	136	119	87	103	124	112	92	222
Total assets	3,831	4,001	4,006	4,229	4,459	4,911	4,606	4,922	5,293
Property, plant & equipment	199	178	164	151	132	172	155	136	267
Capital work-in-progress	5	8	9	0	3	8	8	20	31
Investments	0	0	0	0	0	0	0	0	0
Inventories	457	418	399	434	455	476	500	473	442
Receivables	158	152	174	188	228	193	244	182	241
Cash & equivalents	94	37	16	112	35	495	205	103	93

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	667	356	257	660	968
Cash from investing	-575	-36	54	-71	-562
Cash from financing	-181	-346	-235	-205	-798
Capex	15	65	19	28	25
Free cash flow	652	291	238	632	942
Dividends paid	160	297	183	160	752

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹267 cr5%

CWIP

₹31 cr1%

Inventories

₹442 cr8%

Receivables

₹241 cr5%

Cash & equivalents

₹93 cr2%

Other assets

₹4,218 cr80%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Pfizer Limited	17,641	3,856.00	20.5	4.02	19.6%

StoxGud checklist: Neutral setup · 6/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+1.1%

6 months-18.8%

1 year-26.8%

3Y CAGR-0.5%

5Y CAGR-6.0%

10Y CAGR+8.0%

50-day avg₹4,030.04

200-day avg₹4,562.73

RSI (14)53

FAQs

What is the share price of Pfizer Limited?

Pfizer Limited (PFIZER) closed at ₹3,856.00 on NSE on 06 Nov 2026.

What is the market cap of Pfizer Limited?

₹17,641 crore at the latest close.

What is the P/E ratio of Pfizer Limited?

20.5, on trailing-twelve-month earnings from its filings.

How fast is Pfizer Limited growing?

Pfizer Limited: revenue has compounded at 1.3% a year over three years; net profit at 5.0% a year. Latest-quarter revenue is up 13.2% year on year, profit up 65.7%.

How profitable is Pfizer Limited?

On a trailing-twelve-month basis return on equity is 19.6%, return on capital employed 26.6%, operating margin 36.7%, net margin 32.4%.

How much debt does Pfizer Limited have?

Pfizer Limited is debt-free: debt to equity is 0.00 with borrowings of ₹2 cr against cash of ₹93 cr (balance sheet of 2026-09-30). Operating profit covers interest 131.2 times.

Financials parsed from Pfizer Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.